Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers

Neuropsychopharmacology

Volumn 35, Issue 3, 2010, Pages 806-817

  Guo, Ningning ^a   Guo, Wen ^b   Kralikova, Michaela ^b   Jiang, Man ^a   Schieren, Ira ^b   Narendran, Raj ^a   Slifstein, Mark ^a   Abi Dargham, Anissa ^a   Laruelle, Marc ^a,c,d   Javitch, Jonathan A ^a,b   Rayport, Stephen ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

DA; Endogenous competition; HEK293 cells; Imaging; Raclopride; Sulpiride

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR KINASE 2; QUINPIROLE; RACLOPRIDE; RETINA S ANTIGEN; TETRACYCLINE; TRITIUM;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LIGAND BINDING; MICRODIALYSIS; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR POTENTIAL;

ANIMALS; CATTLE; CELL LINE; DIAGNOSTIC IMAGING; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PROTEIN BINDING; RADIOISOTOPES; RATS; RECEPTORS, DOPAMINE D2;

EID: 75749108170     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.189     Document Type: Article

References (53)

1. 11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 36: 475-483.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
3. 2 receptors. Nucl Med Biol 21: 179-188.
4. 3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for PET studies. J Recept Signal Transduct Res 17: 419-431.
5. 3H]spiperone binding in vivo in rat brain. J Recept Res 11: 163-175.
6. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
7. 11C]raclopride in anesthetized monkeys. In: Gjedde A (ed). Physiological Imaging of the Brain with PET. Academic Press: San Diego. pp 205-209.
8. 18F]fallypride binding in healthy humans. Synapse 62: 399-408.
9. 125I]iodo-2-methoxy- benzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors. J Med Chem 31: 2027-2033.
10. 11C]-(+)-PHNO, a new agonist radio-tracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
11. Goggi JL, Sardini A, Egerton A, Strange PG, Grasby PM (2007). Agonist-dependent internalization of D2 receptors: imaging quantification by confocal microscopy. Synapse 61: 231-241.
12. 3 receptor antagonist ABT-925. Int J Neuropsychopharmacol; e-pub ahead of print 15 Sep 2009, doi:10.1017/S1461145709990642.
13. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, Onorato JJ (1997). Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272: 28849-28852.
14. Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P et al (1997). Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm 104: 329-339.
15. Heusler P, Newmantancredi A, Loock T, Cussac D (2008). Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol 581: 37-46.
16. Honda F, Satoh Y, Shimomura K, Satoh H, Noguchi H, Uchida S et al (1977). Dopamine receptor blocking activity of sulpiride in the central nervous system. Jpn J Pharmacol 27: 397-411. (Pubitemid 8165075)
17. Ichikawa J, Meltzer HY (1992). The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 574: 98-104.
18. Ito K, Haga T, Lameh J, Sadee W (1999). Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur J Biochem 260: 112-119.
19. Javitch JA, Li X, Kaback J, Karlin A (1994). A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. Proc Natl Acad Sci USA 91: 10355-10359.
20. Javitch JA, Shi L, Simpson MM, Chen J, Chiappa V, Visiers I et al (2000). The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 39: 12190-12199.
21. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL et al (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48: 627-640.
22. 2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med 32: 1593-1600.
23. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG (2001). Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and P-arrestins. J Biol Chem 276: 37409-37414.
24. Laruelle M (2000). Imaging neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-451.
25. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, De Souza C, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240.
26. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL et al (1997a). Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17: 162-174.
27. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS et al (1997b). Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14.
28. Leslie CA, Bennett Jr JP (1987). Striatal D1-and D2-dopamine receptor sites are separately detectable in vivo. Brain Res 415: 90-97.
29. 76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. Nucl Med Biol 23: 813-819.
30. Macey TA, Gurevich VV, Neve KA (2004). Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol Pharmacol 66: 1635-1642.
31. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A et al (2007). Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164: 622-629.
32. Mizuchi A, Kitagawa N, Miyachi Y (1983). Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology (Berl) 81: 195-198.
33. 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 1032: 77-84.
34. Namkung Y, Dipace C, Javitch JA, Sibley DR (2009). G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor. J Biol Chem 284: 15038-15051.
35. 11C] fallypride. Synapse 63: 447-461.
36. 11C]-raclopride. Synapse 52: 188-208.
37. 11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495.
38. 11C]NPA) in an anesthetized nonhuman primate. Synapse 61: 106-109.
39. 11C]FLB 457 binding measured by PET. Synapse 41: 87-95.
40. Paspalas CD, Rakic P, Goldman-Rakic PS (2006). Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci 24: 1395-1403.
41. Perry SJ, Lefkowitz RJ (2002). Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 12: 130-138.
42. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63: 782-793.
43. Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG (1996). Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20: 102-110.
44. 18F] fallypride in striatum and extrastriatal regions in humans. Neuropsycho-pharmacology 31: 1016-1026.
45. 1C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry (in submission).
46. 2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54: 46-63.
47. 123I-epidepride in patients with schizophrenia and controls. J Psychiatry Neurosci 22: 39-45.
48. Tsao P, Cao T, von Zastrow M (2001). Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 22: 91-96. (Pubitemid 32146487)
49. van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y et al (2006). Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31: 967-977.
50. Vickery RG, von Zastrow M (1999). Distinct dynamin-dependent and-independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol 144: 31-43.
51. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
52. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
53. 11C]-(+)-4-propyl-3,4,4a,5, 6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.